title: Xenon induces metaphase arrest in rat astrocytes.
abstract: The use of xenon as an almost ideal anesthetic with very little side effects is gaining clinical acceptance, yet its effects on the cellular level are still unclear. It affects intracellular Ca2+-homeostasis but up to now no cellular event or Ca2+-signaling system has been described to be specifically sensitive to xenon. Here we report for the first time a specific effect of xenon on astroglial cells not found with another volatile anesthetic, isoflurane, nor with helium nor with N2: treatment of primary astroglial cells from embryonic rat brain with xenon induces, apart from a slight retardation of the cell cycle, a block at metaphase. Upon removal of xenon cells arrested at metaphase complete their mitosis normally. Even under continuous exposure to xenon, cells can be rescued from metaphase arrest by a small and transient increase in intracellular Ca2+; cells enter anaphase despite the presence of xenon and complete cell division, exhibiting normal rate of chromosome movement and normal chromosome separation. These results suggest that xenon interferes with some Ca2+-dependent regulatory system required for the metaphase-anaphase transition; taking into account its anesthetic effects, xenon may be also involved in the control of glia-mediated signaling transfer.
authors.affiliation: Experimental Anesthesiology, Clinic of Anesthesiology and Intensive Therapy, University Hospital Charité, Humboldt University, Berlin, Germany. christian.petzelt@charite.de
authors.forename: C
authors.initials: C
authors.lastname: Petzelt
authors.forename: G
authors.initials: G
authors.lastname: Taschenberger
authors.forename: W
authors.initials: W
authors.lastname: Schmehl
authors.forename: M
authors.initials: M
authors.lastname: Hafner
authors.forename: W J
authors.initials: WJ
authors.lastname: Kox
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives / Q000494:pharmacology; D000705:Anaphase / Q000187:drug effects; D018685:Anesthetics, Inhalation / Q000494:pharmacology*; D000818:Animals; D001253:Astrocytes / Q000166:cytology / Q000187:drug effects*; D001921:Brain / Q000166:cytology / Q000196:embryology; D002118:Calcium / Q000378:metabolism; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D002478:Cells, Cultured; D020090:Chromosome Segregation / Q000187:drug effects; D006371:Helium / Q000494:pharmacology; D015759:Ionomycin / Q000494:pharmacology; D007530:Isoflurane / Q000494:pharmacology; D008677:Metaphase / Q000187:drug effects*; D008938:Mitosis / Q000187:drug effects; D008940:Mitotic Index / Q000187:drug effects; D009584:Nitrogen / Q000494:pharmacology; D051381:Rats; D013997:Time Factors; D014978:Xenon / Q000494:pharmacology*
chemical_list: D018685:Anesthetics, Inhalation; D006371:Helium; D014978:Xenon; D015759:Ionomycin; C063302:KN 62; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D007530:Isoflurane; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D009584:Nitrogen; D002118:Calcium